Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2024 |
Mar. 31, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Segment Reporting Information [Line Items] | ||||||
| Total revenues | $ 81,504 | $ 30,858 | $ 147,350 | $ 80,427 | ||
| Less: | ||||||
| Cost of sales | 7,492 | 3,464 | 16,322 | 6,720 | ||
| Research and development | 19,453 | 19,298 | 36,996 | 42,439 | ||
| Selling, general and administrative expenses | 69,170 | 58,173 | 133,172 | 112,967 | ||
| Total operating expenses | 96,115 | 80,935 | 186,490 | 162,126 | ||
| Loss from operations | (14,611) | (50,077) | (39,140) | (81,699) | ||
| Other income, net | 2,096 | 5,229 | 4,826 | 9,273 | ||
| Interest expense | (3,029) | (7,484) | (6,011) | (14,964) | ||
| Provision for income taxes | 342 | 0 | 621 | 324 | ||
| Net loss | (15,886) | $ (25,060) | (52,332) | $ (35,382) | (40,946) | (87,714) |
| Reportable Segment | ||||||
| Segment Reporting Information [Line Items] | ||||||
| Total revenues | 81,504 | 30,858 | 147,350 | 80,427 | ||
| Less: | ||||||
| Cost of sales | 6,929 | 3,278 | 12,780 | 6,346 | ||
| Research and development compensation and personnel-related expenses | 9,779 | 9,362 | 19,417 | 19,740 | ||
| Selling, general and administrative expenses | 69,033 | 58,049 | 132,917 | 112,720 | ||
| Other segment expenses | 5,509 | 4,885 | 12,694 | 9,571 | ||
| Total operating expenses | 96,115 | 80,935 | 186,490 | 162,126 | ||
| Loss from operations | (14,611) | (50,077) | (39,140) | (81,699) | ||
| Other income, net | 2,096 | 5,229 | 4,826 | 9,273 | ||
| Interest expense | (3,029) | (7,484) | (6,011) | (14,964) | ||
| Provision for income taxes | 342 | 0 | 621 | 324 | ||
| Net loss | (15,886) | (52,332) | (40,946) | (87,714) | ||
| Topical roflumilast program costs | Reportable Segment | ||||||
| Less: | ||||||
| Research and development | 2,827 | 2,931 | 4,273 | 6,519 | ||
| Topical JAK inhibitor program costs | Reportable Segment | ||||||
| Less: | ||||||
| Research and development | 343 | 595 | 719 | 1,262 | ||
| Other early-stage programs costs | Reportable Segment | ||||||
| Less: | ||||||
| Research and development | $ 1,695 | $ 1,835 | $ 3,690 | $ 5,968 | ||
| X | ||||||||||
- Definition Research and development compensation and personnel-related expenses No definition available.
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|